Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 6, 2005, Pages 589-602

  Berger, Marc A ^a   Masters, Gregg R ^a   Singleton, Judith ^a   Scully, Michael S ^a   Grimm, Lisa G ^a   Soltis, Daniel A ^a   Albone, Earl F ^a,b  

^a PURDUE PHARMA L P   (United States)

^b BioRexis Pharmaceutical Corporation   (United States)

Author keywords

90Y; Biodistribution; CA 125; DOTA; Ovarian cancer; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MONOCLONAL ANTIBODY 776.1 Y 90; CA 125 ANTIGEN; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 776.1; MONOCLONAL ANTIBODY Y 90; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ISOLATION; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INJECTION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IODINE RADIOISOTOPES; MICE; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 30744465920     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.589     Document Type: Article

References (44)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA: Cancer J Clin 2001;51:15.
2. Bast RC, Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 1983;309:883.
3. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001;276:27371.
4. O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348.
5. O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene: A newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002;23:154.
6. Ginath S, Menczer J, Fintsi Y, et al. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer 2002;12:372.
7. Nap M, Vitali A, Nustad K, et al. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 1996;17:325.
8. Leake J, Woolas RP, Daniel J, et al. Immunocytochemical and serological expression of CA 125: A clinicopathological study of 40 malignant ovarian epithelial tumors. Histopathology 1994;24:57.
9. Loy TS, Quesenberry JT, Sharp SC. Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Path 1992;98:175.
10. Beck EP, Moldenhauer A, Merkle E, et al. CA 125 production and release by ovarian cancer cells in vitro. Int J Biol Markers 1998;13:200.
11. Duffy MJ. Clinical uses of tumor markers: A critical review. Crit Rev Clin Lab Sci 2001;38:225.
12. Gohagan JK, Prorok PC, Hayes RB, et al. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Contr Clin Trials 2000;21:251S.
13. Lastoria S, Panza N, Esposito G, et al. Management of patients with ovarian cancer using monoclonal antibodies. Biomed Pharmacother 1992;46:453.
14. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545.
15. Mahe MA, Fumoleau P, Fabbro M, et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 1999;5:3249s.
16. Ab2 OC 125 on the survival rate of ovarian carcinoma patients. Hybridoma 1993;12:567.
17. Davies Q, Perkins AC, Frier M, et al. The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur J Nucl Med 1997;24:206.
18. Pimm MV. Circulating antigen: Bad or good for immunoscintigraphy. Nucl Med Biol 1995;22:137.
19. Pimm MV, Durrant LG, Baldwin RW. Influence of circulating antigen on the biodistribution and tumor localization of radiolabeled monoclonal antibody in a human tumor: Nude mouse xenograft model. Eur J Cancer Clin Oncol 1989;25:1325.
20. Haisma HJ, Battaile A, Stradtman EW, et al. Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer. Int J Cancer 1987;40:758.
21. Singleton J, Guillen DE, Scully MS, et al. Characterization of antibodies to CA125 that bind preferentially to the cell-associated form of the antigen. Tumor Biol (in press).
22. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379.
23. Burbridge MF, Kraus-Berthier L, Naze M, et al. Biological and pharmacological characterization of three models of human ovarian carcinoma established in nude mice: Use of the CA125 tumor marker to predict anti-tumor activity. Int J Oncol 1999;15:1155.
24. Guichard S, Montazeri A, Chatelut E, et al. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokineitic and pharmacodynamic evaluation. Clin Cancer Res 2001;7:3222.
25. 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Rad Oncol Biol Phys 1997;38:419.
26. Dan S, Tsunoda T, Kitahara O, et al. An integrated data-base of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002;62:1139.
27. 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med 2001;42:509.
28. Lewis MR, Kao JY, Anderson AL, et al. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA Bioconj Chem 2001;12:320.
29. Lewis MR, Raubitschek A, Shively JE. A facile, water-soluble method for modification of proteins with DOTA: Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconj Chem 1994;5:565.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248.
31. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999;26:977.
32. Li Q, Hidson W, Wang D, et al. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy. Cancer Immunol Immunother 1998;47:121.
33. Chao TY, Chu TM. Characterization of a new spontaneously developed murine mammary adenocarcinoma in syngeneic BALB/c hosts. In Vitro Cell Dev Biol 1989;25:621.
34. Makoid MC. Multicompartment modeling. In: Makoid MC, Vuchetich PJ, Banakar UV, eds. Basic Pharmacokinetics, First Edition Omaha, NE. (Web publication) 1999;1.
35. Polin L, Valeriote F, White K, et al. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs 1997;15:99.
36. 90Y-labeled antitissue factor antibody. Cancer Biother Radiopharm 2005;20:300.
37. Ng B, Kramer E, Liebes L, et al. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts. Cancer Res 2001;61:2996.
38. 67Cu. Proc Nat Acad Sci 1996;93:6814.
39. 177lutetium-labeled immunoconjugate. Cancer Res 1991;51:2889.
40. 186Re. J Nucl Med 2004;45:327.
41. 131I. J Nucl Med 2001;42:967.
42. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkins' lymphoma. J Nucl Med 2003;44:77.
43. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: Radiolabeling and animal biodistribution studies. Bioconj Chem 1998;9:773.
44. Stimmel JB, Stockstill ME, Kull FC, Jr. Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator. Bioconj Chem 1998;6:219.